Bristol-Myers Squibb

BMY, BMY-R (share classes combined)

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$22.6m

Combined value at quarter end

Last quarter

3 bought

2 sold or trimmed

Price at Q2 ’26 end

$57.62

-5.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+24.6%Q3 ’24

+9.3%Q4 ’24

+7.8%Q1 ’25

-24.1%Q2 ’25

-2.6%Q3 ’25

+19.6%Q4 ’25

+12.4%Q1 ’26

-5.0%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

7Q4 ’23

8Q1 ’24

7Q2 ’24

7Q3 ’24

7Q4 ’24

8Q1 ’25

8Q2 ’25

7Q3 ’25

7Q4 ’25

6Q1 ’26

6Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Bristol-Myers Squibb.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Bristol-Myers Squibb

Kahn Brothers	1.6%$10.0m	$10.0m	Added +2.2%	53 qtrs
Miller Value Partners	0.9%$4.0m	$4.0m	Unchanged	10 qtrs
Tweedy, Browne	0.2%$2.2m	$2.2m	Added +44%	5 qtrs
Horizon Kinetics	0.0%$2.6m	$2.6m	Trimmed -0.3%	30 qtrs
Mairs & Power	0.0%$1.4m	$1.4m	Added +2.0%	53 qtrs
Dodge & Cox	0.0%$2.4m	$2.4m	Trimmed -99%	53 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Bristol-Myers Squibb
		Bought or sold				Filing
9 Sep 2026	Massacesi CristianEVP,Chief Med Offr,Head of Dev	▼ Sold	6,249	$64.57	$403k	Form 4
25 Aug 2026	Holzer Phil MSVP and Controller	▼ Sold	500	$67.50	$34k	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 2.04bn at 22 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$16bn2013

$17bn2015

$21bn2017

$26bn2019

$46bn2021

$45bn2023

$48bn2025

Bristol-Myers Squibb revenue and net income by year
Year	Revenue	Net income
2025	$48bn	$7.1bn
2024	$48bn	−$8.9bn
2023	$45bn	$8.0bn
2022	$46bn	$6.3bn
2021	$46bn	$7.0bn
2020	$43bn	−$9.0bn
2019	$26bn	$3.4bn
2018	$23bn	$4.9bn
2017	$21bn	$1.0bn
2016	$19bn	$4.5bn
2015	$17bn	$1.6bn
2014	$16bn	$2.0bn
2013	$16bn	$2.6bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.